Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.31 |
| ▸ | GABRE | P78334 | 2/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266563 | 0.82 | — | — | |
| SCHEMBL646847 | 0.78 | — | — | |
| SCHEMBL30954536 | 0.76 | GABRP (0.38) | TSHRALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL7609791 | 0.76 | TSHR (0.40) | TSHR | |
| SCHEMBL4705904 | 0.73 | CTSD (0.37) | ALDH1A1 | |
| SCHEMBL2675755 | 0.73 | — | — | |
| SCHEMBL5699118 | 0.72 | HSD17B10 (0.30) | TDP1 | |
| SCHEMBL854379 | 0.71 | GABRR1 (0.38) | CYP1A2 | |
| SCHEMBL17237464 | 0.70 | TSHR (0.41) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL730082 | 0.70 | TSHR (0.41) | TSHRCTHCBSTHPOTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116867789-B | Preparation method of irinotecan derivative and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-116867789-A | Preparation method of irinotecan derivative and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11345691-B2 | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | AbbVie Global Enterprises Ltd. (BM) | 2022-05-31 | — | — | US | disclosed |
| EP-3747882-A1 | PRODRUG MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-12-09 | — | — | EP | disclosed |
| US-20200377491-A1 | Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | GALAPAGOS NV (BE) | 2020-12-03 | — | — | US | disclosed |
| EP-3464282-B1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-04-22 | — | — | EP | disclosed |
| US-10604515-B2 | Heteroaryl substituted pyridines and methods of use | ABBVIE S.Á.R.L. (LU) | 2020-03-31 | — | — | US | disclosed |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-02-21 | — | — | US | disclosed |
| US-10138227-B2 | Heteroaryl substituted pyridines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-11-27 | — | — | US | disclosed |
| US-20170349576-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | ABBVIE S.Á.R.L. (LU) | 2017-12-07 | — | — | US | disclosed |
| US-6204261-B1 | Inhibitors of interleukin-1β Converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-03-20 | — | — | US | disclosed |
| US-6096909-A | Taxoid anti-tumor agents and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5705508-A | FORMING TAXOL DERIVATIVES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
| US-5599820-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0690856-A4 | — | UNIV NEW YORK (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0690856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5475011-A | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1994022856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345691-B2 | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A2, SLC47A1 | TSHR 2273/4885CTH 257/4885CBS 455/4885 |
| US-20170349576-A1 | HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE | CFTR, P2RX2, P2RX1 | TSHR 2256/4885CTH 551/4885CBS 349/4885 |
| US-10604515-B2 | Heteroaryl substituted pyridines and methods of use | CFTR, P2RX2, P2RX1 | TSHR 2256/4885CTH 551/4885CBS 349/4885 |
| US-20190055229-A1 | Heteroaryl Substituted Pyridines and Methods of Use | CFTR, P2RX2, P2RX1 | TSHR 2256/4885CTH 551/4885CBS 349/4885 |
| US-20200377491-A1 | Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A2, SLC47A1 | TSHR 2273/4885CTH 257/4885CBS 455/4885 |
| US-10138227-B2 | Heteroaryl substituted pyridines and methods of use | CFTR, P2RX2, P2RX1 | TSHR 2256/4885CTH 551/4885CBS 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.